

## SCIENTIFIC PROGRAM\*

(\*Subject to change)

**Wednesday, 6 March, 2024**

13:00-14:30	<b>PLENARY INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)					
14:30-14:40	Break to Change Halls					
14:40-16:10	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>#dedoc° Symposium WHAT WE WISH YOU KNEW – AND WHY (14:40 – 16:00)</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)
16:10-16:20	Break to Change Halls					
16:20-17:50	<b>PLENARY INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)					
18:00-18:40	<b>OPENING SESSION</b>					
	<b>Moshe Phillips</b> - Opening Remarks <b>Melanie Davies</b> – A new era in the management of T2DM and obesity – Scanning what's on the horizon					
18:40-19:00	<b>OPENING EVENT</b>					
19:00-20:00	<b>NETWORKING RECEPTION (in the Exhibition Area)</b>					

Thursday, 7 March, 2024

08:00-08:20	ONLINE FIRST RELEASE							
08:20-09:00	SCIENTIFIC SESSION - TBD							
09:00-10:00	PLENARY 1 - TOWARD THE FUTURE							
	<b>Moshe Phillip</b> - From dream to reality - The Automated Insulin Delivery (AID) system <b>Boris Kovatchev</b> - Neural-Net artificial pancreas <b>Camillo Ricordi</b> - From the first-in-human success in stem cell derived Islet Transplantation to a cure for all patients with diabetes: Challenges, requirements, and possible solutions							
10:00-10:30	COFFEE BREAK, EXHIBITION & E-POSTERS							
10:30-12:00	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)							
12:00-13:00	LUNCH BREAK, EXHIBITION & E-POSTERS							
13:00-14:30	<b>PARALLEL SESSION 1</b> <b>AUTOMATED INSULIN DELIVERY IN TYPE 1 AND TYPE 2 DIABETES</b>	<b>PARALLEL SESSION 2</b> <b>CGM DIABETES QUALITY MEASURES</b>	<b>PARALLEL SESSION 3</b> <b>HYPOGLYCEMIA - ANY PROGRESS?</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> <small>(not included in the main event CME/CPD credit)</small>	<b>JDRF - PARALLEL SESSION 4</b> <b>INTERNATIONAL CONSENSUS MONITORING GUIDANCE FOR PRESYMPTOMATIC (EARLY STAGE) TYPE 1 DIABETES</b>	<b>PARALLEL SESSION 5</b> <b>INTERVENTION AND PREVENTION OF TYPE 1 DIABETES</b>	<b>PARALLEL SESSION 6</b> <b>COPING WITH OBESITY</b>	<b>ORALS 1</b>
	<b>Anders Carlson</b> – Use of AID in patients with type 2 diabetes <b>Roman Hovorka</b> - Fully closed-loop in type 1 and type 2 diabetes <b>Bruce Bode</b> - Management of glucose in the hospital with AID systems <b>May Ng</b> - Bringing technology to diabetes care - From evidence to policy	<b>Irl Hirsch</b> - What has the GMI taught us about A1C? <b>Elisabeth Selvin</b> - Should A1C still be a diagnostic criterion for diabetes in 2024? <b>Gregg Simonson</b> – CGM (GMI/TIR) as diabetes quality metrics <b>Guido Freckmann</b> - International standard for evaluation of CGM systems: Approach of the IFCC	<b>Stephanie Amiel</b> – CGM detection of hypoglycemia in diabetes management <b>Simon Heller</b> - Should the classification of hypoglycemia be updated? <b>Pratik Choudhary</b> - Implication of HypoMETRICS for reporting hypoglycemia in clinical trials <b>Bastiaan de Galan</b> - Impaired awareness of hypoglycemia		<b>Moshe Phillip</b> - The rationale for consensus monitoring guidance for presymptomatic type 1 diabetes <b>Linda DiMeglio</b> - Summary of the consensus monitoring guidance for presymptomatic type 1 diabetes <b>Kirstine Bell</b> - Implications for research and clinical care <b>Emanuele Bosi</b> - Population screening for type 1 diabetes is now a reality: An update from Italy	<b>Teresa Rodriguez-Calvo</b> - Role of viruses in pathogenesis of type 1 diabetes <b>Rohit Kulkarni</b> - Targeting mRNA modifications to counter type 1 diabetes <b>Roberto Mallone</b> - Benign autoimmunity & progression to type 1 diabetes <b>Desmond Schatz</b> – Enhancing our understanding of why type 1 diabetes develops. Lessons learned from organ donors	<b>Emma Wilmot</b> – Technology-supported behavior intervention in type 2 diabetes <b>Max Nieuwdorp</b> - A balanced view on microbiome in obesity <b>Luca Busetto</b> – Will new pharmacological treatment for obesity and early diabetes replace bariatric surgery? <b>Primož Kotnik</b> Managing severe obesity in pediatric population	

14:30-14:40	Break to Change Halls							
14:40-16:10	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)							
16:10-16:40	COFFEE BREAK, EXHIBITION & E-POSTERS							
16:40-18:10	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL SESSION 7 STANDARDIZATION OF PROS</b>	<b>ORALS 2</b>	<b>PARALLEL SESSION 8 ROLE OF TECHNOLOGY IN NORMAL HEALTHY AND IN GDM PREGNANCY</b>	<b>PARALLEL SESSION 9 THE EFFECT OF DIABETES ON BRAIN HEALTH</b>	<b>PARALLEL SESSION 10 HYBRID CLOSED-LOOP FOR TYPE 2 DIABETES - HURDLES AND BENEFITS</b>	<b>PARALLEL SESSION 11 ACCESSIBILITY AND DISPARITIES OF DIABETES THERAPY</b>	<b>ORALS 3</b>
	<p><b><u>Oliver Schnell</u></b> - What PROs mean in routine clinical care</p> <p><b><u>Katharine Barnard-Kelly</u></b> - Consensus statement summary, navigating the maze of PROs</p> <p><b><u>Mary Murphy</u></b> - What inclusion of quality PRO assessment in clinical trials means to people with diabetes</p> <p><b><u>Alon Liberman</u></b> – Real world data from type 1 diabetes clinics</p>		<p><b><u>Celeste Durnwald</u></b> – Can CGM replace the oral glucose tolerance test for diagnosis of gestational diabetes?</p> <p><b><u>Eleanor Scott</u></b> - CGM glucose trajectories associated with large and small for gestational age birthweight</p> <p><b><u>Helen Murphy</u></b> – Should everyone with type 1 diabetes be offered closed-loop during pregnancy?</p> <p><b><u>Yariv Yogeve</u></b> - Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation?</p>	<p><b><u>Mark Strachan</u></b> - Update on diabetes-associated cognitive dysfunction</p> <p><b><u>Tali Cukierman-Yaffe</u></b> - Diagnosis &amp; monitoring of brain health in people with diabetes</p> <p><b><u>Hertzel Gerstein</u></b> - Brain aging in people with diabetes - Possible intervention</p> <p><b><u>David Tanne</u></b> - Novel approaches and the role of technology in treating brain aging in people with diabetes</p>	<p><b><u>Yves Reznik</u></b> - Closed-loop as home care for type 2 diabetes: The Close study</p> <p><b><u>Charlotte Boughton</u></b> - Cumulated experience with CamAPS in type 2 diabetes</p> <p><b><u>Gregory Forlenza</u></b> - Real-world data on hybrid closed-loop (HCL) in type 2 diabetes</p> <p><b><u>Anne Peters</u></b> - Pod use for closed-loop in type 2 diabetes</p>	<p><b><u>Lori Laffel</u></b> - Interventions to reduce health disparities in diabetes device use</p> <p><b><u>V Mohan</u></b> – Innovating to use existing technologies under resourced settings</p> <p><b><u>Partha Kar</u></b> - Widening clinical use of diabetes tech in the UK</p> <p><b><u>Stuart Weinzimer</u></b> - Strategies to facilitate technology use in disadvantaged youth with diabetes</p> <p><b><u>Ananta Addala</u></b> - Solutions for equity: A call to action</p>		

**Friday, 8 March, 2024**

08:30-09:20	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)							
09:20-09:30	Break to change halls							
09:30-10:30	<b>EUDF - PARALLEL SESSION 12 AI DRIVEN CLINICAL DECISION SUPPORT SYSTEMS - POTENTIAL, CONCERNS AND WHAT TO EXPECT?</b>	<b>PARALLEL SESSION 13 DUAL AND TRIPLE AGONISTS IN DIABETES AND OBESITY</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL SESSION 14 SKIN PROBLEMS IN DIABETES</b>	<b>PARALLEL SESSION 15 WEEKLY INSULINS</b>	<b>PARALLEL SESSION 16 PRACTICAL USE OF CGM</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>ORALS 4</b>
	<b>Stefano Del Prato</b> – Welcome and introduction  <b>Lutz Heinemann</b> - AI for diabetes management and state-of-the art today  <b>Mia Barjamagic</b> - Potential & concerns linked to the use of AI from the PwD perspective  <b>Tadej Battelino</b> - Implementing AI: Roadmap and guidelines  Q&A and Discussion	<b>Viral Shah</b> – GLP-1RA and SGLT in type 1 diabetes  <b>Michael Camilleri</b> - Pharmacological intervention with dual and triple agonists in obesity: Clinical efficacy and effects on stomach emptying  <b>Andrej Janež</b> – Incretins and taste		<b>Anna Korsgaard Berg</b> - Skin problems caused by diabetes devices  <b>Julia Mader</b> - Lipohypertrophy and its effect on glucose control/insulin uptake/causes/detection/training and awareness of HCP and PwD  <b>Deirdre Fitzgerald Huges</b> - Shining a light on diabetic foot infections, development of novel photodynamic materials	<b>Julio Rosenstock</b> – Update on weekly insulin Icodec: The way of the future  <b>Juan Frias</b> – Update on weekly insulin Efsitora  <b>Chantal Mathieu</b> – CGM derived data on weekly insulins	<b>Cari Berget</b> - Technology pearls for professionals  <b>Steven Edelman</b> – Top 10 tips to help people with diabetes (PwD) stay in range  <b>Steven Edelman and Jeremy Pettus</b> – Rapid fire interpretations of CGM downloads		
10:30-11:00	COFFEE BREAK, EXHIBITION & E-POSTERS							

11:00-12:30	<b>PLENARY INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)
12:30-13:30	<b>LUNCH BREAK, EXHIBITION &amp; E-POSTERS</b>
13:30-15:00	<b>PLENARY 2 ATTD YEARBOOK SESSION</b>
	<p><b><u>Klemen Dovc</u></b> - Continuous and intermittent glucose monitoring</p> <p><b><u>Rayhan A. Lal</u></b> - Insulin delivery hardware: pumps and pens</p> <p><b><u>Lutz Heinemann</u></b> - New insulins, biosimilars and insulin therapy</p> <p><b><u>Mark Clements</u></b> - Closed-loop, artificial intelligence-based decision support systems and data science</p> <p><b><u>Mark Clements</u></b> - Using digital health technology to prevent and treat diabetes</p> <p><b><u>Jennifer M. Yamamoto</u></b> - Technology and pregnancy</p> <p><b><u>David M. Maahs</u></b> - Diabetes technology and therapy in the pediatric age group</p> <p><b><u>Dessi P. Zaharieva</u></b> - Advances in exercise and nutrition as therapy in diabetes</p> <p><b><u>Thomas W. Martens</u></b> - Primary care and diabetes technologies and treatments</p> <p><b><u>Medha Munshi</u></b> - Use of technologies at the advanced age</p> <p><b><u>Ananta Addala</u></b> - Diabetes technology in the “real world”: Expanding access and addressing disparities</p> <p><b><u>Alon Liberman</u></b> - Diabetes technology and the human factor</p> <p><b><u>Desmond Schatz</u></b> - Immune interventions and restorative therapies in type 1 diabetes</p> <p><b><u>Viral N. Shah</u></b> - Obesity, NAFLD/NASH and diabetes</p> <p><b><u>Satish K. Garg</u></b> - Virtual clinics for diabetes care</p> <p><b><u>Satish K. Garg</u></b> - New medications for the treatment of diabetes</p>
15:00-15:15	Break
15:15-16:45	<b>PLENARY INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)
16:45-17:15	<b>COFFEE BREAK, EXHIBITION &amp; E-POSTERS</b>

17:15-18:45	<b>PARALLEL SESSION 17 OBESITY IN TYPE 1 DIABETES</b>	<b>PARALLEL SESSION 18 AUTOMATED INSULIN DELIVERY IN CHILDREN</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>PARALLEL SESSION 19 SELF MANAGEMENT OF DIABETES</b> (17:15-18:05)	<b>PARALLEL SESSION 20 CGM GUIDED PRECISION DIABETES MANAGEMENT</b>	<b>PARALLEL SESSION 21 INTEROPERABILITY OF DIABETES TECHNOLOGY</b>	<b>PARALLEL INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)	<b>ORALS 5</b>
	<p><b>Satish Garg</b> - Management options for treating obesity in type 1 diabetes patients</p> <p><b>Jeremy Pettus</b> - Insulin resistance in type 1 diabetes: An underappreciated problem</p> <p><b>Kirsten Nørgaard</b> - Effects of GLP1 in type 1 diabetes</p> <p><b>Victor Gerdes</b> - Bariatric surgery in diabetes</p>	<p><b>Revital Nimri</b> - Maximizing glycemic control with automated insulin delivery in young children</p> <p><b>Thomas Danne</b> – Worldwide progress achieving treatment targets in children with type 1 diabetes</p> <p><b>Ivana Rabbone</b> - Technology in the changing management of diabetes in children</p> <p><b>Nataša Bratina</b> - Data on diabetes treatment in children below the age of six</p>		<p><b>Mark Clements</b> – Just in time adaptive interventions: The new technology to “hack” diabetes self-management behavior</p> <p><b>John Leth</b> - The potential of open-source software in diabetes research</p> <p><b>Heiko Peuscher</b> - A survey on existing open-source projects in diabetes simulation</p>	<p><b>Tara Ettestad</b> - CGM Guided Nutrition</p> <p><b>Michael Riddell</b> - CGM guided exercise</p> <p><b>Thomas Martens</b> – CGM guided insulin management</p> <p><b>Darja Šmigoc Schweiger</b> - Guided management of diabetes in female</p>	<p><b>David Klonoff</b> – Interoperability of diabetes technology Academic view</p> <p><b>Alexander Olbrechts</b> - Interoperability of diabetes technology - A company's view</p> <p><b>Johan Jendle</b> - Interoperability of diabetes technology - Regulatory hurdle</p> <p><b>Tim Street</b> – Interoperability of diabetes technology - Patient's view</p>		
18:45-18:55								
18:55-20:25	<b>IGNITE Start-up Networking Event</b> (not included in the main event CME/CPD credit)				<b>ATTD Partner Event</b> (not included in the main event CME/CPD credit)			

## Saturday, 9 March, 2024

08:30-09:20	<b>PLENARY INDUSTRY SYMPOSIUM</b> (not included in the main event CME/CPD credit)						
09:20-09:30	Break to Change Halls						
09:30-11:00	<b>PARALLEL SESSION 23 DECISION SUPPORT AND AUTOMATED INSULIN DELIVERY FOR THE MANAGEMENT OF TYPE 2 DIABETES</b>	<b>PARALLEL SESSION 24 CHALLENGES IN METABOLIC CONTROL</b>	<b>ORALS 6</b>	<b>PARALLEL SESSION 25 CGM CLINICAL WORKFLOW</b>	<b>PARALLEL SESSION 26 SCREENING, INTERVENTION AND PREVENTION OF TYPE 1 DIABETES</b>	<b>PARALLEL SESSION 27 NUTRITION AND FOOD TECHNOLOGIES</b>	<b>ORALS 7</b>
	<p><b><u>Chiara Fabris</u></b> - Simulation-enhanced closed-loop adaptation of long-acting insulin dosing in T2D</p> <p><b><u>Lia Bally</u></b> - Virtual clinic for insulin therapy in type 2 diabetes</p> <p><b><u>Morten Hasselstrøm Jensen</u></b> - Adherence through cloud-based personalized treatment for Type 2 diabetes: The ADAPT-T2D project</p>	<p><b><u>Richard Bergenstal</u></b> - We need to clear the FOG (Feet on the Ground) hyperglycemia in order to minimize hyperglycemia</p> <p><b><u>Elisabeth Selvin</u></b> - Diabetes and cognitive decline and dementia</p> <p><b><u>Francesco Giorgino</u></b> - Addressing glucose patterns in type 2 diabetes: Opportunities and challenges</p> <p><b><u>Nebojsa Lalic</u></b> - Achievement of optimal time in range and glucose variability in pump treated type 1 diabetes patients with diabetic kidney disease</p>		<p><b><u>David Maahs</u></b> - Early CGM initiation in pediatric type 1 diabetes: Equity and logistical considerations from the 4T Study</p> <p><b><u>Amy Criego</u></b> – CGM Success: Device start and ongoing data management to improve patient care</p> <p><b><u>Nana Jones</u></b> - Integration of CGM data into the EMR – Challenges and successes</p> <p><b><u>Xavier Cos</u></b> - Use of CGM by the primary care providers</p>	<p><b><u>Emanuele Bosi</u></b> – Universal screening for risk of type 1 diabetes: Can it be an effective prevention tool?</p> <p><b><u>Laura Jacobsen</u></b> – Immune therapy – Predicting responders/non-responders</p> <p><b><u>Jennifer Sherr</u></b> – Teplizumab therapy in the real world</p> <p><b><u>Raffaella Buzzetti</u></b> – Antibody positivity in adult population</p>	<p><b><u>Michal Gillon-Keren</u></b> - Facilitate carb counting for people with diabetes</p> <p><b><u>Laya Ekhlaspour</u></b> - Beyond carbohydrate counting: Optimizing mealtime insulin dosing</p> <p><b><u>Peter Jacobs</u></b> - Unannounced meal detection algorithms: Can we eliminate manual meal boluses?</p> <p><b><u>Daria Igudesman</u></b> - Diet, microbiome, obesity and type 1 diabetes</p>	

11:00-11:30	<b>COFFEE BREAK, EXHIBITION &amp; E-POSTERS</b>							
11:30-13:00	<b>PARALLEL SESSION 28 TO CGM OR NOT TO CGM?</b>	<b>PARALLEL SESSION 29 SPORT IN DIABETES</b>	<b>ORALS 8</b>	<b>PARALLEL SESSION 30 GENDER DIFFERENCES IN DIABETES MANAGEMENT AND GLUCOSE CONTROL</b>	<b>JDRF - PARALLEL SESSION 31 CELL REPLACEMENT THERAPY</b>	<b>PARALLEL 32 ADVANCES IN TREATING DIABETES</b>	<b>PARALLEL SESSION 33 TECHFAIR WINNERS' PRESENTATIONS</b>	<b>ORALS 9</b>
	<p><b><u>Tadej Battelino</u></b> - CGM derived criteria for stage 2 type 1 diabetes</p> <p><b><u>Leon Farhy</u></b> – Diagnostic CGM</p> <p><b><u>Anders Carlson</u></b> - The use of CGM in prediabetes and obesity</p> <p><b><u>Dario Rahelic</u></b> - Use of CGM in nutrition management in type 2 diabetes</p>	<p><b><u>Klemen Dovc</u></b> - Automated insulin delivery around exercise in type 1 diabetes: Individualization versus generalizability</p> <p><b><u>Michael Riddell</u></b> - Lessons learned from the ongoing type 1 diabetes exercise research initiative</p> <p><b><u>Kirsten Nørgaard</u></b> - Low-dose glucagon to prevent hypoglycemia during exercise</p> <p><b><u>Dessi Zaharieva</u></b> - Translation of exercise guidelines into practical applications for type 1 diabetes</p>		<p><b><u>Eda Cengiz</u></b> - Update on diabetes Female Technology (femtech)</p> <p><b><u>Chiara Fabris</u></b> - What do women want (and need)? Results from the large-scale IMAGINE survey</p> <p><b><u>Jane Yardley</u></b> - Challenges of exercise in women with type 1 diabetes</p> <p><b><u>Brynn Marks</u></b> - Insulin delivery is automated, but the education is not: Mothering diabetes technology users</p>	<p><b><u>Ester Latres</u></b> - Introduction</p> <p><b><u>Peter Senior</u></b> - 20-year outcomes of islet cell transplantation - The benchmark for stem cells?</p> <p><b><u>Qizhi Tang</u></b> - Engineering beta cells to enable immunosuppression-free replacement therapy for type 1 diabetes</p> <p><b><u>José Oberholzer</u></b> - Islet cell replacement therapy for type 1 diabetes</p> <p>Round Table</p>	<p><b><u>Peter Adolfsson</u></b> - Current use of connected pens</p> <p><b><u>Fernando Gómez Peralta</u></b> - Connected insulin pens and caps: An expert's recommendation from the area of diabetes of the Spanish Endocrinology and Nutrition Society (SEEN)</p> <p><b><u>Christophe de Block</u></b> – Ketone continuous measurement – Is it needed?</p> <p><b><u>Andrea Facchinetti</u></b> - Digital twin technologies for treating diabetes</p> <p><b><u>Neal Kaufman</u></b> - The importance and impact of family caregivers on a variety of outcomes for people with diabetes</p>		



13:00-13:45	<b>LUNCH BREAK, EXHIBITION &amp; E-POSTERS</b>						
13:45-15:15	<b>PARALLEL SESSION 34 OBESITY AND TYPE 2 DIABETES</b>	<b>PARALLEL SESSION 35 DIABETES IN ITALY</b>	<b>ORALS 10</b>	<b>ISPAD/ATTD - PARALLEL SESSION 36 DIABETES TECHNOLOGY IN LOWER INCOME COUNTRIES</b>	<b>PARALLEL SESSION 37 DTECH SYMPOSIUM - DIABETES IN INDIA</b>	<b>PARALLEL SESSION 38 SARCOPENIA, FRAILITY AND DIABETES</b>	<b>ORALS 11</b>
	<p><b><u>Antonio Ceriello</u></b> - Weight and glycemic variability: Bad companions for CVD development in diabetes</p> <p><b><u>Kamlesh Khunti</u></b> - Early intervention for type 2 diabetes in primary care</p> <p><b><u>Barbara McGowan</u></b> - Medical therapies for treatment of obesity</p> <p><b><u>Jernej Kovac</u></b> - Genetic background of obesity</p>	<p><b><u>Marco Marigliano</u></b> - Relationships between insulin delivery system, CGM satisfaction and glucometrics</p> <p><b><u>Andrea Scaramuzza</u></b> - Real-world data in very young AHCL users - Comparison among different systems</p> <p><b><u>Nicola Minuto</u></b> - Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough</p> <p><b><u>Sergio di Molfetta</u></b> - CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated</p>		<p><b><u>Renza Scibilia</u></b> – Type 1 diabetes global index and overview of diabetes technology present and future in lower income countries</p> <p><b><u>Thereza Piloya-Were</u></b> - Impact of CGM in East Africa, research and translation</p> <p><b><u>Hamidah Nabakka</u></b> - Diabetes advocate perspective on diabetes technology in low-income countries</p>	<p><b><u>Banshi Saboo</u></b> - Welcome and introduction to Dtech symposium</p> <p><b><u>Shashank Joshi</u></b> - Artificial intelligence in diabetes care</p> <p><b><u>Jothydev Kesavadev</u></b> - 25 years of telemedicine vs. conventional care in diabetes: Assessing vascular complications and quality of life</p> <p><b><u>Manoj Chawla</u></b> - Optimizing real time CGM in self-pay markets</p> <p><b><u>Amit Gupta</u></b> - Challenges and opportunities in digital diabetes care in India</p> <p><b><u>Mithun Bhartia</u></b> - Diabetes and sex life – The role of technology to improve quality of life</p> <p><b><u>Rakesh Parikh</u></b>: Artificial Intelligence in the management of diabetes</p>	<p><b><u>Alan Sinclair</u></b> - Diabetes, sarcopenia and frailty: Interrelationships and clinical importance</p> <p><b><u>Leocadio Rodríguez Mañas</u></b> - Current treatment options for sarcopenia in the context of frail older people with diabetes</p> <p><b><u>Tali Cukierman-Yaffe</u></b> - How to measure and monitor sarcopenia and frailty</p> <p><b><u>TBC</u></b> - Current and investigational medication for sarcopenia</p>	

15:15-15:25	Break to Change Halls
15:25-16:25	<b>PLENARY 3</b> <b>CURE OF DIABETES</b>
	<b><u>Michael Haller</u></b> - Cost effectiveness of immune therapies in preserving beta cell function – Real world applications <b><u>Jay Skyler</u></b> - Stem cell approaches to type 1 diabetes <b><u>Michael Rickels</u></b> - Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes
16:25-17:00	<b>CLOSING REMARKS</b>
17:00	<b>FAREWELL REFRESHMENTS</b>